Fundz Deep Dive
Everything you need to win Laekna (2105.HK) & Eli Lilly and Company — in one platform.
Who to reach, what to say, and why now on Laekna (2105.HK) & Eli Lilly and Company — plus every funding round, exec hire, and M&A move that follows, each with the verified contact and the outreach written for you.
Get the full Deep Dive on Laekna (2105.HK) & Eli Lilly and Company — free.
One free Deep Dive, emailed to you. No spam; unsubscribe anytime.
Ready now? Choose your plan · Request a demo · Sign in
Engage writes the reply
Grounded in signals no one else has — tuned to their persona.
Signals no one else has
UCC liens, benefit plans, 13F holdings, permits, exec moves — fused.
Verified contact + click-to-call
The decision-maker’s email and mobile — dial in-browser.
Laekna Announces Clinical Collaboration with Lilly to Develop LAE102 Monoclonal Antibody for the Treatment of Obesity
Nov 20, 2024•over 1 year ago
Contract Type
partnership
Los AngelesBiotechnologyHealth CareDescription
Laekna, Inc. has announced a clinical collaboration with Eli Lilly and Company to develop LAE102, an ActRIIA antagonistic mAb as a novel treatment for obesity. The collaboration will focus on the clinical evaluation of LAE102, which may have potential as a first-in-class therapy in this disease area.
Agreement Insights
Based on industry dataStrategic partnership established
Partnership agreements typically involve technology integration and joint go-to-market strategies
Contract momentum indicator
Companies with recent agreements are 2.3x more likely to make additional purchases within 6 months